Protease-activated receptor 1 (PAR1) has been demonstrated to be involved in the pathogenesis of viral diseases. However, its role remains controversial. The goal of our study was to investigate the contribution of PAR1 to respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections.
Introduction
Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are members of the new Pneumoviridae family of non-segmented, negative-stranded, enveloped RNA viruses. hMPV is a member of Metapneumovirus genus whereas RSV belongs to the Orthopneumovirus genus (Afonso et al., 2016) . Both viruses are major causes of acute respiratory tract infections. RSV is the second most important cause of death worldwide among children below the age of 5 years, responsible for up to 250 000 deaths a year (Lozano et al., 2012) . Unfortunately, there is currently no licensed vaccine to prevent RSV and hMPV infections and their treatment is still limited to the use of Ribavirin, a weakly effective antiviral agent, and immunoglobulins (Drysdale et al., 2016; Esposito and Mastrolia, 2016) . The most severe forms of RSV and hMPV infections are associated with both significant inflammatory pathology as well as excessive virus replication (DeVincenzo et al., 2010; Rosenberg and Domachowske, 2012; Roussy et al., 2014) . In such a context, anti-inflammatory and/or antiviral therapies may lead to more effective control of RSV and hMPV infections.
Protease-activated receptors (PARs) belong to the superfamily of GPCRs and has four members: PAR1-4. PAR1 was the first family member discovered, consisting of 425 amino acids with a thrombin cleavage site between residues 41 and 42, and is known as the highest affinity thrombin receptor (Vu et al., 1991; Sidhu et al., 2014) . It was first identified for its role in platelet activation and initiation of the coagulation cascade (Vu et al., 1991) . Subsequently, PAR1 has been demonstrated to be involved in multiple physiological and pathological processes, such as thrombosis, wound healing, inflammation, embryonic development and cancer progression (Vergnolle, 2009; Gieseler et al., 2013) .
The involvement of PAR1 in viral infections has been reported in the case of herpesvirus, influenza virus, coxsackievirus, dengue virus and hMPV (Scholz et al., 2004; Sutherland et al., 2007; Cabello-Gutiérrez et al., 2009; Aerts et al., 2013; Antoniak et al., 2013; Khoufache et al., 2013; Antoniak and Mackman, 2014; Mackman and Antoniak, 2014) . However, this receptor seems to exert a dual role, notably in herpesvirus and influenza virus infections. Indeed, Scholz et al. (2004) suggested that thrombin/PAR1-mediated Sp1 phosphorylation inhibits human cytomegalovirus replication in retinal pigment epithelial cells, whereas Pryzdial's team found a significant increase of herpesvirus replication in endothelial cells and fibroblasts after PAR1 activation (Sutherland et al., 2007) . With regard to influenza, Riteau's team reported that PAR1 contributed to the deleterious inflammatory response in the lungs and increased the pathogenesis of the virus (Khoufache et al., 2013) . In contrast, Antoniak et al. (2013) showed that PAR1 increased the immune response to influenza virus infection and thereby inhibited virus replication.
In most studies, TFLLR-NH 2 and SCH79797 have been used as PAR1 agonist and antagonist, respectively, for assessing the involvement of PAR1 in viral infections (Sutherland et al., 2012; Aerts et al., 2013; Khoufache et al., 2013) . However, while SCH79797 has been demonstrated as a specific human PAR1 antagonist, its specificity in mice is controversial (Di Serio et al., 2007; Pawlinski et al., 2007) .
The use of non-specific tools might explain the divergent results on the role of PAR1 in infectious diseases. PAR1 is of great interest in drug development (French et al., 2015) and particularly for the design of novel antivirals targeting the host instead of the virus. Thus, it is of crucial importance to better understand its role during viral infections. Here, we aimed to investigate the role of PAR1 during RSV and hMPV infections using more specific tools. In addition to the PAR1-specific agonist TFLLR-NH 2 , we used for the first time RWJ-56110, an indole-based peptide mimetic and highly specific PAR1 antagonist (Andrade-Gordon et al., 1999; Derian et al., 2003; Maryanoff et al., 2003) , which has also been shown to specifically inhibit the murine PAR1 (Andrade-Gordon et al., 1999; Kaufmann et al., 2005) .
We showed that PAR1 has a deleterious effect during RSV and hMPV infections, acting both on viral replication and inflammation. Thus, these results suggest that PAR1 is a promising target for the development of novel antivirals against RSV and hMPV infections.
Methods

Cells and viruses
Hep-2 and LLC-MK2 cells (ATCC, Manassas, VA, USA) were maintained in minimal essential medium (Thermo Fisher Scientific, Burlington, ON, Canada) supplemented with 10% FBS (Wisent, Saint-Jean-Baptiste, QC, Canada) and HEPES buffer (2.5 g·L À1 ). A549 and NIH/3T3 cells (ATCC) were maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% FBS and 1% penicillin-streptomycin (Thermo Fisher Scientific). The RSV strains A2 (ATCC) were grown in Hep-2 cells and concentrated by ultracentrifugation at 141 000× g for 2 h at 4°C using Optima ™ L-90 ultracentrifuge with SW 28 Ti rotor (Beckman Counter, Montreal, QC, Canada). The hMPV strain C85473, a clinical isolate, was grown in LLC-MK2 cells and concentrated in a similar manner and schedule at room temperature. The RSV and hMPV virus titres were determined by immunostaining as previously described (Deffrasnes et al., 2008; Persson et al., 2014) . Virus titres are expressed as plaque-forming units (PFU) mL À1 . To determine the effect of TFLLR-NH 2 , RWJ-56110 or argatroban on ERK phosphorylation during RSV and hMPV infections in vitro, A549 cells were treated with or without 50 μM of TFLLR-NH 2 and incubated at 37°C for 5 min, 10 μM of RWJ-56110 or 100 μM of argatroban and incubated at 37°C for 1 h. DMEM medium or DMSO (Sigma Aldrich) served as mock PAR1 agonist and antagonist or argatroban treatments respectively. The cells were then uninfected or infected with 30 PFU of RSV or 300 PFU of hMPV. Cell lysates were collected at 5 and 30 min post-infection for Western blot analysis of ERK phosphorylation.
Cytotoxicity assessment
To investigate the capacity of RSV and hMPV to activate PAR1, A549 cells were infected with 30 PFU of RSV or 300 PFU of hMPV per well. DMEM medium served as uninfected control. Cells were harvested at 5 and 30 min and lysed for Western blot analysis of PAR1 activation.
Western blot analysis
Equal protein amounts were separated on 10% SDS-PAGE gels and then transferred to nitrocellulose membranes (GE HealthCare Life Sciences, Mississauga, ON, Canada) and blocked using 5% BSA (Sigma Aldrich). Primary antibodies were used at a dilution of 1:1000 rabbit anti-phospho-ERK, rabbit anti-ERK (Cell Signaling Technology, Boston, MA, USA), mouse anti-PAR1 (R&D Systems, Minneapolis, MN, USA), rabbit anti-cleaved-Ser42 PAR1 (Biorbyt, San Francisco, CA, USA) and mouse anti-α-tubulin (Sigma Aldrich). Secondary antibodies were used at a dilution of 1:5000 HRP-conjugated mouse anti-rabbit, rabbit anti-mouse (Cell Signaling Technology).
Signal detection was carried out using the West Pico Plus Chemiluminescent Substrate (Thermo Fisher Scientific).
Ethics statement
Six-week-old female BALB/c mice with a body weight of 16.5-18 g were purchased from Charles River Laboratories (Senneville, QC, Canada). This animal strain is widely used for the study of RSV and hMPV infections (Domachowske et al., 2004; Schildgen et al., 2007) . Mice were housed under pathogen-free conditions in the animal research facility of the Quebec University Health Centre (Quebec City, QC, Canada) and allowed to acclimatize for 1 week prior to the start of experiments. All in vivo studies were approved by the Animal Protection Committee of the Quebec University Health Centre in accordance with the guidelines of the Canadian Council on Animal Care (Protocol number: CPAC 2013-082-3) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . The animals were killed by CO 2 inhalation if humane end points were reached (weight loss ≥20% of preexperimental body weight).
In vivo viral infections, PAR1 treatments and thrombin inhibition
Mice were anaesthetized by inhalation of isoflurane vaporized at concentrations of 3-4% and oxygen flow rate adjusted to 1.5 L·min
À1
. The assessment of anesthetic depth is based on six parameters recommended by the Animal Protection Committee of the Quebec University Health Centre including the following: heart rate, respiratory rate, capillary refill time, body temperature, mucous membrane color and palpebral reflex. They were then infected intranasally with RSV (3 × 10 6 PFU per mouse) or hMPV at two different doses: 0.5 × 10 6 (non-lethal dose) or 10 6 (LD 50 dose) PFU per mouse. Equal volumes of Opti-MEM medium (25 μl) served as mock infection. At the same time, mice were treated, by intranasal instillation, with 10 μl of 500 μM of TFLLR-NH 2 or RWJ-56110. Equivalent dilutions of Opti-MEM medium served as control. These treatments were repeated once a day for four consecutive days. PAR1 agonist TFLLR-NH 2 and antagonist SCH79797 have been previously tested at two doses: 50 and 500 μM. We found that the higher dose (500 μM) was better than the low dose (50 μM) for investigating the role of PAR1 in hMPV infection in mice (Aerts et al., 2013) . Therefore, we decided to use this dose for both PAR1 agonist TFLLR-NH 2 and antagonist RWJ-56110 in this study. For thrombin inhibition, mice were injected i.p. with argatroban at a dose of 9 mg·kg À1 (Asanuma et al., 2004) . They were then immediately infected with RSV or hMPV. The treatment with argatroban was repeated once a day for four consecutive days during infections. Control mice were given DMSO in a similar manner. Individual body weight and clinical signs were used to monitor animal health and response to infection and were recorded daily for 2 weeks.
Lung viral titrations
To evaluate virus titres on day 5 post-infection, mice were killed by cervical dislocation under isoflurane anaesthesia and whole lungs were harvested and then homogenized in PBS (1 mL per sample) using a TH Tissue Homogenizer (Omni International, Kennesaw, GA, USA). The supernatants were BJP V B Lê et al.
collected after centrifugation at 350× g for 10 min at 4°C. The RSV and hMPV virus titres were determined by immunostaining and expressed as PFU g À1 of the lung.
Broncho-alveolar lavage and cell counting
On day 5 post-infection, mice were killed by cervical dislocation under isoflurane anaesthesia, and broncho-alveolar lavage (BAL) was performed with PBS. The cells in the lavage fluid were pelleted by centrifugation at 300× g for 5 min at 4°C and then suspended in PBS, whereas BAL supernatants were collected for evaluating inflammatory and coagulation parameters with the exception of tissue factor (TF). The measurement of TF was carried out in the fluids of BAL with and without centrifugation. Viable cell number was determined using a haemocytometer and expressed as number mL À1 of BAL. For differential cell counts, 100 μL of suspended cells were spun onto a slide by using a Shandon Cytospin ™ 3 cytocentrifuge (Thermo Fisher Scientific) at 100× g for 5 min at room temperature. Slides were then air-dried and stained with May-Grunewald Giemsa solutions (Sigma Aldrich) according to the manufacturer's instructions. Differences in cell counts were made by using standard morphological criteria and counting at least 300 cells per sample. The results are expressed as different percentages. 
BAL cytokine and total protein quantification
Measurement of thrombin-antithrombin (TAT) and TF levels
The levels of TAT and TF in BAL supernatants were determined using a TAT mouse ELISA kit (Abcam, Toronto, ON, Canada) and Mouse Coagulation Factor III/TF DuoSet ELISA (R&D Systems) following the manufacturer's instructions and the results are expressed as ng or pg·mL À1 of BAL supernatants.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology Curtis et al. (2015) . All group data subjected to statistical analysis have a minimum of n = 5 independent samples from different individuals per group for reliable P values. All statistical tests were conducted using the GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). The results are expressed as the mean ± SEM for each group. Survival data were analysed by comparing Kaplan-Meier curves using the log-rank test. Virus titres, cytokines, chemokines, total protein levels, immune cell recruitment, cell differentiation, TAT and TF levels were analysed using two-way ANOVA followed by Tukey's post hoc test. Differences were considered statistically significant when P < 0.05.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
Cytotoxicity of PAR1 agonist TFLLR-NH 2 and antagonist RWJ-56110, PAR4 agonist AY-NH 2 and thrombin inhibitor argatroban
The CC 50 concentrations of these compounds are presented in Figure 1A . In the case of PAR1 and PAR4 agonists, the CC 50 concentrations could not be determined because no cell death was observed at the highest tested dose of these two peptides (0.8 mM). In a previous study, we demonstrated that the PAR1 antagonist SCH79797, which is currently used in the majority of models of viral infections, was extremely toxic for cells (Aerts et al., 2013) . Herein, we showed that the PAR1 antagonist RWJ-56110 has almost no toxic effects on at least two cell types: Hep-2 and LLC-MK2 (CC 50 > 0.7 mM). The selectivity of RWJ-56110 to PAR1 has been demonstrated previously (Andrade-Gordon et al., 1999) . Herein, the selectivity of this compound was confirmed by evaluating its capacity to inhibit PAR4 activation-induced ERK phosphorylation in NIH/3T3 cells since PAR1 activation has been demonstrated to phosphorylate ERK (Khoufache et al., 2013) . We found that RWJ-56110 inhibited ERK phosphorylation induced by the PAR1 agonist TFLLR-NH 2 , but not by PAR4 agonist AY-NH 2 ( Figure 1B) .
Western blot analysis revealed a decreased PAR1 gene expression resulting from siRNA transfection in A549 cells, which was consistent with previous findings (Liu et al., 2004) . RSV and hMPV replication in control negative siRNAtransfected cells treated with RWJ-56110 did not significantly differ from that of cells undergoing siRNA knockdown of PAR1 gene expression. Moreover, RWJ-56110 treatment did not modulate the viral titres in siRNA-transfected cells ( Figure 1C) . Thus, RWJ-56110 can be used as a novel potential PAR1 antagonist for studying the involvement of PAR1 in various physiological or pathological processes.
RWJ-56110 exhibited an antiviral effect against RSVand hMPV in A549 cells
To investigate the role of PAR1 in RSV and hMPV replication, A549 cells were infected with 30 PFU of RSV or 300 PFU of hMPV and treated with the indicated concentrations of TFLLR-NH 2 or RWJ-56110. By counting infected cells identified by immunostaining, we showed that RWJ-56110 treatment significantly reduced both RSV and hMPV titres in a dose-dependent manner. In contrast, PAR1 activation had no influence on the replication of these viruses ( Figure 1E ). These results show that RSV and hMPV replication is increased via PAR1 in vitro. In parallel, we detected that ERK was phosphorylated in RSV-and hMPV-infected cells after 30 min of infection ( Figure 1F ). These findings were consistent with those showing that both RSV and hMPV induce PAR1 activation after 30 min of infection, as indicated by the cleavage of PAR1 ( Figure 1D ). In other words, RSV and hMPV promoted ERK activation by activating PAR1, as previously reported (Wang et al., 2002; Khoufache et al., 2013) . In agreement with Figure 1E , TFLLR-NH 2 did not have an additive effect to that of the viruses on ERK phosphorylation whereas RWJ-56110 inhibited virus-induced ERK phosphorylation ( Figure 1F ). The inhibition of virus-triggered ERK phosphorylation could be related to the decreased viral replication resulting from RWJ-56110 treatment, and the lack of effect of TFLLR-NH 2 in these conditions is because ERK phosphorylation has been demonstrated to be required for RSV infection (Monick et al., 2001; Pazdrak et al., 2002; Kong et al., 2004) .
RWJ-56110 reduced weight loss and prevented mortality in RSV-and hMPV-infected mice
In vivo, TFLLR-NH 2 -triggered PAR1 activation did not significantly affect RSV infection. However, there was an increased mortality of hMPV-infected mice receiving this agonist, as compared to untreated animals. Consistent with a deleterious role of PAR1 in these settings, RWJ-56110 reduced weight loss for both RSV-and hMPV-infected mice at non-lethal doses (3 × 10 6 PFU of RSV and 0.5 × 10 6 PFU of hMPV per mouse) (Figure 2A ). TFLLR-NH 2 treatment reduced only and moderately the survival of hMPV-infected mice. Consistent with other reports, infections with RSV, even at very high dose of infection, did not increase mouse mortality (Meng et al., 2014) ; no protection by RSV could thus be observed, and TLLFR-NH 2 did not affect the survival of these treated mice. However, when mice were challenged with hMPV at an LD 50 dose (10 6 PFU per mouse), RWJ-56110 treatment Figure 2 Time course of RSV-and hMPV-induced pathogenesis and survival rate in mice in response to RWJ-56110 treatment. (A) Mice were infected with RSV or hMPV at sublethal doses and treated with Opti-MEM medium, TFLLR-NH 2 or RWJ-56110. (B) Mice were infected with hMPV at an LD 50 dose and treated with Opti-MEM medium or RWJ-56110. They were monitored for weight loss for 14 days after infection and killed if humane end points were reached. Results are average % weight loss ± SEM or average % survival (n = 10 per group, *P < 0.05 TFLLR-NH 2 vs. control or RWJ-56110 vs. Opti-MEM).
fully protected the mice from a fatal outcome ( Figure 2B ). Altogether, these results show that PAR1 plays a deleterious role in the pathogenesis of RSV and hMPV.
Protective effect of RWJ-56110 treatment on viral replication and inflammation
To determine the effect of RWJ-56110 treatment on viral replication and inflammation, mice were infected with 3 × 10 6 PFU of RSV or 10 6 PFU of hMPV and the lung homogenates as well as BAL fluids were harvested at day 5 post-infection to assess lung viral titres, leukocyte recruitment, alteration of alveolar-capillary permeability as well as inflammatory cytokine and chemokine production. The results showed that RWJ-56110 treatment substantially reduced viral loads in the lungs as well as the total concentration of proteins in BAL of both RSV-and hMPV-infected mice ( Figure 3A , B). Although total leukocyte recruitment was influenced by RWJ-56110 treatment ( Figure 3C ), no difference in the proportion of leukocytes (macrophages, lymphocytes and neutrophils) between untreated and RWJ-56110-treated groups was observed ( Figure 3D ). Thus, RWJ-56110 decreases the recruitment of all leukocytes instead of a particular cell type.
In addition, the levels of the cytokines G-CSF, IL-3, IL-4, IL-6, IL-10, IL-12(p40), IL-12(p70), IL-17, KC and MCP-1 were decreased in the BAL of RSV-and hMPV-infected mice treated with RWJ-56110 in comparison to infected/untreated mice (Figure 4) . In contrast, RWJ-56110 treatment specifically induced a decrease in IL-5 levels during RSV infection whereas a decrease in IFN-γ levels and an increase in IL-9 levels were seen during hMPV infection ( Figure 5 ). The concentrations of other cytokines and chemokines (eotaxin, GM-CSF, IL-1α, IL-1β, IL-2, IL-13, MIP-1α, MIP-1β, RANTES and TNF-α) were not influenced by the RWJ-56110 treatment.
RWJ-56110 affects thrombin generation
Since PAR1 is a thrombin receptor (Kahn et al., 1998) , we next examined whether coagulation is initiated upon RSV and hMPV infections. To this end, mice were infected with 3 × 10 6 PFU of RSV or 10 6 PFU of hMPV, and at day 5 postinfection, BAL fluids were harvested to analyse TAT levels, a surrogate marker of thrombin generation. The results presented in Figure 6A show that TAT levels are increased upon RSV and hMPV infections in comparison to uninfected mice. Thus, both RSV and hMPV could activate the coagulation cascade, leading to thrombin generation. Interestingly, when infected mice were treated with RWJ-56110, a significant Figure 3 Protective effect of RWJ-56110 after virus challenge. Mice were infected with RSV or hMPV and treated with Opti-MEM medium, TFLLR-NH 2 or RWJ-56110. Five days after infection, mice were killed and the lungs and BAL fluids were collected for evaluating (A) viral replication in the lungs, (B) BAL total protein, (C) BAL leukocyte recruitment and (D) BAL cell differentiation (n = 5 per group, *P < 0.05 RWJ-56110 vs. Opti-MEM).
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decrease in TAT levels was observed in comparison with untreated mice. These findings led us to hypothesize that RSVand hMPV-triggered activation of PAR1 occurs upstream of thrombin generation that, in turn, increases the pathogenesis of these infections.
To test this possibility, thrombin was inhibited by using the direct specific thrombin inhibitor argatroban that blocks thrombin-catalysed or -induced reactions (Yoshinaga et al., 2003; Dhillon, 2009) . As expected, argatroban had no effect on the replication of RSV and hMPV, in vitro ( Figure 6B ), since
Figure 4
Profile of cytokines and chemokines in response to RWJ-56110 during RSV and hMPV infections. Mice were infected or not with RSV or hMPV and treated with Opti-MEM medium, TFLLR-NH 2 or RWJ-56110. Five days after infection, mice were killed and BAL fluids were collected for evaluating the profile of cytokines and chemokines (n = 5 per group, *P < 0.05 RWJ-56110 vs. Opti-MEM).
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there is no source of prothrombin, TF or factor X in these conditions. Furthermore, argatroban treatment also did not increase the level of ERK phosphorylation in virus-infected cells ( Figure 6C ), which was shown to be required for the viral replication ( Figure 1F ). In contrast, argatroban treatment provided a full protection from RSV-and hMPV-induced pathogenesis and death. Interestingly, co-treatment of the mice with argatroban and RWJ-56110 did not improve the protective effect of argatroban, reinforcing our hypothesis that PAR1 might lead to thrombin generation ( Figure 6D ).
Argatroban protected mice from viral replication and inflammation
To better define the effect of the treatment with argatroban, viral replication and inflammation were assessed in the lung homogenates and BAL fluids of RSV-or hMPV-infected mice treated or not with argatroban. The results show that argatroban treatment significantly reduced pulmonary virus loads in vivo as well as leukocyte recruitment and concentrations of total protein in the lungs (Figures 7A-C) . Interestingly, argatroban treatment also induced a decreased in the pulmonary levels of G-CSF, IL-3, IL-4, IL-6, IL-1α, IL-12(p40), IL-12(p70), IL-17, KC and MCP-1 upon RSV and hMPV infections (Figure 8 ). In contrast, argatroban treatment specifically induced a decrease in IL-5 levels during RSV infection whereas a specific decrease in IFN-γ and IL-10 levels and an increase in IL-9 levels were observed during hMPV infection (Figure 9) . Notably, we observed that in all these experiments, the effect of argatroban treatment was very similar to that of RWJ-56110, with the exception to its effects on IL-1α and IL-10, and that co-treatment did not provide an additional inhibitory effect on these parameters. The differences in IL-1α and IL-10 secretion in response to RWJ-56110 treatment in two separate experiments might be due to the slightly different virulence of the virus stocks despite similar quantities of virus administered to the animals.
PAR1 activation was not dependent on thrombin generation during viral infections
To firmly establish the mechanism by which PAR1 plays a deleterious role in viral infections, TAT and TF were evaluated in the fluids of BAL. Figure 10A shows that treatments with RWJ-56110 alone or combined treatment with RWJ-56110 and argatroban significantly diminished TAT levels in RSV-and hMPV-infected mice. Moreover, TAT levels were not different between RWJ-56110-treated groups and argatroban-treated groups. These data again confirm that the effect of RWJ-56110 occurs upstream of thrombin generation. Furthermore, TF levels were elevated in the non-centrifuged BAL of infected groups (but not after centrifugation), as compared to control uninfected groups, consistent with the expression of TF at the surface of inflammatory cells infiltrating the lungs. Treatment with RWJ-56110 alone significantly decreased TF levels in both RSV-and hMPV-infected groups whereas treatment with argatroban alone did not affect the quantity of TF. Finally, a combination of argatroban with RWJ-56110 had no additional effect over that of RWJ-56110 alone ( Figure 10B ). These data indicate that PAR1 activation does not depend on thrombin generation during viral infections and also suggest that PAR1 activation is involved in the virus pathogenesis upstream of thrombin generation via inflammation-triggered TF activity.
Discussion
In the present study it was shown that PAR1 plays a detrimental role during hMPV and RSV infections. In vitro, blocking
Figure 5
Profile of IFN-γ, IL-5 and IL-9 in response to RWJ-56110 during RSV and hMPV infections. Mice were infected or not with RSV or hMPV and treated with Opti-MEM medium, TFLLR-NH 2 or RWJ-56110. Five days after infection, mice were killed and BAL fluids were collected for evaluating the profile of cytokines and chemokines (n = 5 per group, *P < 0.05 RWJ-56110 vs. Opti-MEM).
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Figure 6
Thrombin is involved in the pathogenesis of RSV and hMPV. (A) Mice were infected with RSV or hMPV and treated with Opti-MEM medium or RWJ-56110. Five days after infection, mice were killed and the BAL fluids were collected for evaluating TAT levels (n = 5 per group, *P < 0.05 RWJ-56110 vs. Opti-MEM). (B, C) Antiviral effect of argatroban was investigated in vitro. Hep-2 or LLC-MK2 cells were treated with argatroban and then infected with RSV or hMPV. Virus-infected cells were identified by immunostaining and counted (n = 6 per group). In parallel, A549 cells were treated or not with argatroban and then infected with RSV or hMPV. The cells were harvested for Western blot analysis of ERK phosphorylation. (D) Mice were injected with DMSO or argatroban and infected with RSV or hMPV. Animals were treated in parallel with Opti-MEM medium or RWJ-56110. They were monitored for weight loss for 14 days after infection and killed if humane end points were reached. Results are average % weight loss ± SEM or average % survival (n = 10 per group).
PAR1 antagonist protects against RSV and hMPV infections BJP PAR1 by using the specific antagonist RWJ-56110 inhibited virus replication. Thus, PAR1 increases the infectivity of both hMPV and RSV. In agreement with these in vitro results, stimulating PAR1 with its specific agonist TFLLR-NH 2 increased hMPV pathogenesis in mice, while treating the mice with the antagonist RWJ-56110 had the opposite effect. Thus, our findings show that PAR1 plays a detrimental role during RSV and hMPV infections. These results are consistent with our previous findings showing that PAR1 inhibition by SCH79797 exerts an antiviral effect against this virus by preventing furin-induced cleavage of hMPV fusion protein (Aerts et al., 2013) . To our knowledge, this is the first time that PAR1 has been demonstrated to be involved in RSV infections. RSV and hMPV use distinct mechanisms to interfere with the host's innate and adaptive immune responses (Guerrero-Plata et al., 2005; Guerrero-Plata et al., 2006) . Despite these differences, blocking PAR1 activation had beneficial effects on both viruses.
In the present study, TFLLR-NH 2 did not appear to provide a substantial increase in viral replication, in vitro. One possible explanation for this result is that this PAR1 agonist does not add appropriate signals in nature or intensity to those induced by the viruses. The absence of an effect of TFLLR-NH 2 on the level of ERK phosphorylation observed in these infected cells favours this hypothesis. Indeed, although there are no findings to support a relationship between ERK phosphorylation and hMPV replication, it has been demonstrated that ERK phosphorylation is critical for RSV infection (Monick et al., 2001; Pazdrak et al., 2002; Kong et al., 2004) . In contrast, PAR1 inhibition by RWJ-56110 displayed a potent antiviral effect. This could presumably be explained by the fact that RSV and hMPV can effectively activate PAR1 by themselves, as demonstrated in Figure 1D . We were able to demonstrate the protective effect of PAR1 inhibition on hMPV-induced mortality, in vivo. Unfortunately, we could not do this for RSV because the BALB/c mice are only semipermissive to RSV with it having no effect on the survival rate of these mice (Meng et al., 2014) . However, the ability of PAR1 inhibition to protect these mice from weight loss allowed us to conclude that PAR1 inhibition by RWJ-56110 may provide protection against RSV and hMPV infections.
PAR1 is a thrombin receptor whose activation is triggered by proteolytic cleavage of its extracellular N-terminal domain, notably by thrombin or other proteases (Vu et al., 1991) . Thrombin has been reported to contribute to the pathogenesis of several viruses (Dubovi et al., 1983; Sutherland et al., 2007 Sutherland et al., , 2012 Hsue et al., 2012; Lin et al., 2012; Antoniak et al., 2013; Boilard et al., 2014; Bondu et al., 2015) . To our knowledge, little is known about the involvement of thrombin in the pathogenesis of RSV and hMPV infections. Indeed, only one study has shown that thrombin increases RSVinduced cell fusion in A549 cells (Dubovi et al., 1983) , whereas there is no report about the involvement of thrombin in hMPV infection. It was evident that, similar to PAR1 inhibition by RWJ-56110, thrombin inhibition by argatroban resulted in significantly less weight loss and mortality and decreased viral replication and inflammation in infected mice. Therefore, we can conclude that thrombin plays an essential role in the pathogenesis of RSV and hMPV infections. There is a strong bidirectional link between inflammation and the activation of the coagulation cascade with inflammatory cells providing TF, and in turn thrombin generation itself is responsible for leukocyte recruitment and, therefore, exacerbates inflammation during infections (Chen and Dorling, 2009) . Moreover, no difference in the antiviral effect was found between single and combined RWJ-56110 and argatroban treatments.
The coagulation system is schematically divided into three pathways: the extrinsic, intrinsic and common pathways. In the extrinsic pathway, the TF/FVIIa complex is the key initiator of the coagulation protease cascade and activates both FIX and VX, leading to the formation of thrombin (Mackman, 2009) . Here, we measured TF levels in the noncentrifuged and centrifuged fluids of BAL and found that RSV and hMPV induced an elevation of TF levels in the non-centrifuged samples. Thus, the major sources of TF in RSV and hMPV infections were probably leukocytes recruited in infected lungs or microparticles, as previously reported (Bastarache et al., 2009; Pawlinski et al., 2010) . Interestingly, TF levels were decreased by PAR1 inhibition, but not by thrombin inhibition, indicating that PAR1 activation occurred via an unknown thrombin-independent pathway. Further studies are required to clarify the mechanisms of RSV-and hMPV-induced PAR1 activation. Moreover, Figure 7 Protective effect of thrombin inhibition after virus challenge. Mice were injected with DMSO or argatroban and infected with RSV or hMPV. Animals were treated in parallel with Opti-MEM medium or RWJ-56110. Five days after infection, mice were killed and the lungs and BAL fluids were collected for evaluating (A) viral replication in the lungs, (B) BAL total protein and (C) leukocyte recruitment (n = 5 per group, *P < 0.05 RWJ-56110; argatroban or argatroban/RWJ-56110 vs. DMSO).
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decreased TF levels due to PAR1 inhibition correlated with decreased TAT levels. In other words, PAR1 activation occurs upstream of thrombin and modulates TF exposure. This results in uncontrolled thrombin generation, which in turn plays a detrimental role during RSV and hMPV infections.
Previous reports have shown that PAR1 induces an adverse effect during influenza virus infections through plasminogen (Khoufache et al., 2013) , which itself acts through fibrinolysis . Thus, altogether, these results suggest that PAR1 activation upon viral infection dysregulates haemostasis, leading to a more severe disease. Once activated, PAR1 generally exerts a pro-inflammatory effect such as mast cell degranulation, increased vascular permeability, cytokine release and leukocyte recruitment, which may exacerbate inflammation (Vergnolle et al., 2002) . In contrast to our study, PAR1 has been reported to protect against pathogens in some instances (Scholz et al., 2004; Kaneider et al., 2007; Wee et al., 2010; Antoniak et al., 2013; Chionh et al., 2015) . Potentially, PAR1 may have different roles according to the pathogens and host models.
Figure 8
Profile of cytokines and chemokines in response to thrombin inhibition during RSV and hMPV infections. Mice were injected with DMSO or argatroban. Thereafter, they were infected or not with RSV or hMPV. They were treated in parallel with Opti-MEM medium or RWJ-56110. Five days after infection, mice were killed and the BAL fluids were collected for evaluating the profile of cytokines and chemokines (n = 5 per group, *P < 0.05 RWJ-56110; argatroban or argatroban/RWJ-56110 vs. DMSO).
Alternatively, it is known that a well-regulated immune response to infection plays a protective role in contrast to the dysregulated excessive inflammation. Thus, as discussed by Berri et al. (2014) , the role of PAR1 in viral infection may be dual, protective during a mild viral infection and deleterious during a severe viral infection.
In summary, we demonstrate here, for the first time, that PAR1 inhibition by RWJ-56110 exerts an antiviral effect against both RSV and hMPV. We also showed that the antiviral effect of RWJ-56110 results in the blockade of TFmediated thrombin generation during pneumovirus infections. Finally, the present study highlights the importance of thrombin depletion by using its inhibitor argatroban or PAR1 inhibition by using its antagonists RWJ-56110 for attenuating the consequences of RSV and hMPV infections, including weight loss, mortality, virus loads, lung tissue injuries and inflammation in mice. Thus, the use of thrombin inhibitors or PAR1 antagonists may have potential as a novel and Figure 9 Profile of IFN-γ, IL-5, IL-9 and IL-10 in response to thrombin inhibition during RSV and hMPV infections. Mice were injected with DMSO or argatroban. Thereafter, they were infected or not with RSV or hMPV. They were treated in parallel with Opti-MEM medium or RWJ-56110. Five days after infection, mice were killed and the BAL fluids were collected for evaluating the profile of cytokines and chemokines (n = 5 per group, *P < 0.05 RWJ-56110; argatroban or argatroban/RWJ-56110 vs. DMSO).
Figure 10
Profile of TAT and TF in response to thrombin inhibition during RSV and hMPV infections. Mice were injected with DMSO or argatroban. Thereafter, they were infected or not with RSV or hMPV. They were treated in parallel with Opti-MEM medium or RWJ-56110. Five days after infection, mice were killed and the BAL fluids were collected for evaluating the profile of TAT and TF (n = 5 per group, *P < 0.05 RWJ-56110 or argatroban/ RWJ-56110 vs. DMSO; argatroban vs. argatroban/RWJ-56110; RWJ-56110 vs. argatroban).
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efficacious strategy for the prevention and/or treatment of RSV and hMPV infections that warrant additional studies.
